Skip to main content

Table 3 Changes in severity of ultrasound (US) and magnetic resonance imaging (MRI) abnormalities from baseline to week 12

From: Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab

  

Hips

Shoulders

Four joints

Bursitisa

 US

Improvement

13% (4/30)

57% (16/28)

34% (20/58)

No change

77% (23/30)

18% (5/28)

48% (28/58)

Worsening

10% (3/30)

25% (7/28)

17% (10/58)

 MRI

Improvement

73% (22/30)

29% (8/28)

52% (30/58)

No change

27% (8/30)

61% (17/28)

43% (25/58)

Worsening

0% (0/30)

11% (3/28)

5% (3/58)

Effusion/synovitisb

 US

Improvement

47% (14/30)

32% (9/28)

40% (23/58)

No change

50% (15/30)

57% (16/28)

53% (31/58)

Worsening

3% (1/30)

11% (3/28)

7% (4/58)

 MRI

Improvement

33% (10/30)

32% (9/28)

32% (19/58)

No change

57% (17/30)

57% (16/28)

57% (33/58)

Worsening

10% (3/30)

11% (3/28)

10% (6/58)

  1. aBursitis: subacromial bursitis at the shoulders and trochanteric and iliopsoas bursitis at the hips
  2. bShoulders: glenohumeral joint and long head of biceps; hips: coxofemoral joints